Published in J Gene Med on March 01, 2009
Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers. Mol Ther (2010) 1.29
The sodium iodide symporter (NIS) as an imaging reporter for gene, viral, and cell-based therapies. Curr Gene Ther (2012) 1.18
Secreted blood reporters: insights and applications. Biotechnol Adv (2011) 0.96
The use of the NIS reporter gene for optimizing oncolytic virotherapy. Expert Opin Biol Ther (2015) 0.91
Homologous recombination in E3 genes of human adenovirus species D. J Virol (2013) 0.85
Potentiation of tumor radiotherapy by a radiation-inducible oncolytic and oncoapoptotic adenovirus in cervical cancer xenografts. Int J Cancer (2011) 0.82
Epitope dampening monotypic measles virus hemagglutinin glycoprotein results in resistance to cocktail of monoclonal antibodies. PLoS One (2013) 0.81
Evaluation of adenovirus capsid labeling versus transgene expression. Virol J (2010) 0.78
Preferable sites and orientations of transgene inserted in the adenovirus vector genome: The E3 site may be unfavorable for transgene position. Gene Ther (2015) 0.76
Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation (1998) 4.10
A mutant herpes simplex virus type 1 thymidine kinase reporter gene shows improved sensitivity for imaging reporter gene expression with positron emission tomography. Proc Natl Acad Sci U S A (2000) 3.28
Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood (2003) 2.67
A simple and efficient method for purification of infectious recombinant adenovirus. Jpn J Med Sci Biol (1994) 1.97
Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation (1999) 1.82
Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides. Nat Med (2002) 1.80
Adenovirus-mediated expression of human coagulation factor IX in the rhesus macaque is associated with dose-limiting toxicity. Blood (1999) 1.70
Repeat administration of an adenovirus vector encoding cystic fibrosis transmembrane conductance regulator to the nasal epithelium of patients with cystic fibrosis. J Clin Invest (1996) 1.70
Assays for noninvasive imaging of reporter gene expression. Nucl Med Biol (1999) 1.62
Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs. J Virol (1999) 1.61
Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer. Science (1999) 1.57
Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter. Clin Cancer Res (2006) 1.47
Adenovirus biodistribution and noninvasive imaging of gene expression in vivo by positron emission tomography using human sodium/iodide symporter as reporter gene. Hum Gene Ther (2002) 1.39
Human reporter genes: potential use in clinical studies. Nucl Med Biol (2007) 1.33
In vivo quantitation of intratumoral radioisotope uptake using micro-single photon emission computed tomography/computed tomography. Mol Imaging Biol (2006) 1.30
Variability of adenovirus receptor density influences gene transfer efficiency and therapeutic response in head and neck cancer. Clin Cancer Res (1999) 1.23
The Na/I symporter (NIS): imaging and therapeutic applications. Semin Nucl Med (2004) 1.22
Kinetics of serum tumor marker concentrations and usefulness in clinical monitoring. Clin Chem (1999) 1.20
Sensitivity and reproducibility in adenoviral infectious titer determination. Nat Med (1997) 1.17
A method to codetect introduced genes and their products in gene therapy protocols. Nat Biotechnol (1996) 1.16
Genetically targeted radiotherapy for multiple myeloma. Blood (2003) 1.15
Long-term expression of human coagulation factor VIII and correction of hemophilia A after in vivo retroviral gene transfer in factor VIII-deficient mice. Proc Natl Acad Sci U S A (1999) 1.15
Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo. Cancer Res (2001) 1.12
Combined I-124 positron emission tomography/computed tomography imaging of NIS gene expression in animal models of stably transfected and intravenously transfected tumor. Mol Imaging Biol (2006) 1.12
Carcinoembryonic antigen production, secretion, and kinetics in BALB/c mice and a nude mouse-human tumor model. Cancer Res (1984) 1.11
A quantitative nonimmunogenic transgene product for evaluating vectors in nonhuman primates. Mol Ther (2000) 1.08
Adenovirus-mediated and targeted expression of the sodium-iodide symporter permits in vivo radioiodide imaging and therapy of pancreatic tumors. Hum Gene Ther (2006) 1.04
Catheter-mediated vascular endothelial growth factor gene transfer to human coronary arteries after angioplasty. Hum Gene Ther (2000) 1.03
Noninvasive imaging of therapeutic gene expression using a bidirectional transcriptional amplification strategy. Mol Ther (2008) 1.02
Noninvasive monitoring of therapeutic gene transfer in animal models of muscular dystrophies. Gene Ther (2006) 1.00
Carcinoembryonic antigen: clinical application. Cancer (1976) 1.00
Assessing tumors in living animals through measurement of urinary beta-human chorionic gonadotropin. Nat Med (2000) 1.00
Tight positive regulation of transgene expression by a single adenovirus vector containing the rtTA and tTS expression cassettes in separate genome regions. Hum Gene Ther (2003) 0.99
Disappearance curves for tumor markers after resection of intrathoracic malignancies. Int J Biol Markers (1999) 0.98
PET reporter genes for noninvasive imaging of gene therapy, cell tracking and transgenic analysis. Crit Rev Oncol Hematol (2004) 0.97
Dynamic iodide trapping by tumor cells expressing the thyroidal sodium iodide symporter. Biochem Biophys Res Commun (2004) 0.94
Use of a murine secreted alkaline phosphatase as a non-immunogenic reporter gene in mice. J Gene Med (2005) 0.92
Design considerations for incorporating sodium iodide symporter reporter gene imaging into prostate cancer gene therapy trials. Hum Gene Ther (2007) 0.87
Monitoring adenoviral p53 transduction efficiency by yeast functional assay. Gene Ther (1998) 0.85
Gene therapy for thyroid cancer: current status and future prospects. Thyroid (2004) 0.82
Quantitative RT-PCR to evaluate in vivo expression of multiple transgenes using a common intron. Biotechniques (1999) 0.81
Development of a dual membrane protein reporter system using sodium iodide symporter and mutant dopamine D2 receptor transgenes. J Nucl Med (2007) 0.77
Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA (2003) 13.79
Improved survival in multiple myeloma and the impact of novel therapies. Blood (2007) 12.70
Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation (2006) 11.78
Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med (2005) 5.94
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood (2005) 5.82
Oncolytic virotherapy. Nat Biotechnol (2012) 5.79
Left atrial volume as a morphophysiologic expression of left ventricular diastolic dysfunction and relation to cardiovascular risk burden. Am J Cardiol (2002) 4.56
Engineering targeted viral vectors for gene therapy. Nat Rev Genet (2007) 3.69
Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol (2002) 3.68
Natural history of asymptomatic mitral valve prolapse in the community. Circulation (2002) 3.40
E2-2 protein and Fuchs's corneal dystrophy. N Engl J Med (2010) 3.31
Prediction of risk for first age-related cardiovascular events in an elderly population: the incremental value of echocardiography. J Am Coll Cardiol (2003) 3.20
Left atrial volume: a powerful predictor of survival after acute myocardial infarction. Circulation (2003) 3.08
Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc (2006) 2.88
Genomic association analysis identifies multiple loci influencing antihypertensive response to an angiotensin II receptor blocker. Hypertension (2012) 2.86
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc (2009) 2.86
Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood (2003) 2.67
Left atrial volume as an index of left atrial size: a population-based study. J Am Coll Cardiol (2003) 2.62
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc (2013) 2.59
Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc (2007) 2.55
Prediction of cardiovascular outcomes with left atrial size: is volume superior to area or diameter? J Am Coll Cardiol (2006) 2.55
History of oncolytic viruses: genesis to genetic engineering. Mol Ther (2007) 2.51
Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol (2009) 2.50
Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. J Am Coll Cardiol (2002) 2.50
Left atrial volume predicts cardiovascular events in patients originally diagnosed with lone atrial fibrillation: three-decade follow-up. Eur Heart J (2005) 2.45
Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood (2011) 2.45
Rescue and propagation of fully retargeted oncolytic measles viruses. Nat Biotechnol (2005) 2.40
Association of ambulatory blood pressure with ischemic brain injury. Hypertension (2007) 2.39
Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc (2007) 2.34
For estimating creatinine clearance measuring muscle mass gives better results than those based on demographics. Kidney Int (2009) 2.32
Mortality trends in patients diagnosed with first atrial fibrillation: a 21-year community-based study. J Am Coll Cardiol (2007) 2.32
Survival in patients with poorly compressible leg arteries. J Am Coll Cardiol (2012) 2.25
A critique on contemporary reporting of likelihood ratios in test power analysis. Mayo Clin Proc (2004) 2.23
Outcome of 622 adults with asymptomatic, hemodynamically significant aortic stenosis during prolonged follow-up. Circulation (2005) 2.20
Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res (2010) 2.19
The prevalence of atrial fibrillation in incident stroke cases and matched population controls in Rochester, Minnesota: changes over three decades. J Am Coll Cardiol (2003) 2.19
Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res (2002) 2.18
Engineering microRNA responsiveness to decrease virus pathogenicity. Nat Med (2008) 2.14
High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer Res (2004) 2.14
Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood (2009) 2.12
Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Cancer Res (2003) 2.12
Measurement and quality control issues in multiplex protein assays: a case study. Clin Chem (2009) 2.11
Consecutive 1127 therapeutic echocardiographically guided pericardiocenteses: clinical profile, practice patterns, and outcomes spanning 21 years. Mayo Clin Proc (2002) 2.08
Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma. J Clin Oncol (2013) 2.01
Circulating MMP2 and MMP9 in breast cancer -- potential role in classification of patients into low risk, high risk, benign disease and breast cancer categories. Int J Cancer (2006) 2.00
Incidence and mortality risk of congestive heart failure in atrial fibrillation patients: a community-based study over two decades. Eur Heart J (2006) 1.97
Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci. Am J Hum Genet (2012) 1.96
Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component. Mayo Clin Proc (2009) 1.96
Antibody-based protein multiplex platforms: technical and operational challenges. Clin Chem (2009) 1.95
The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood (2006) 1.94
Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood (2012) 1.91
Plasma renin activity predicts blood pressure responses to beta-blocker and thiazide diuretic as monotherapy and add-on therapy for hypertension. Am J Hypertens (2010) 1.90
Comparison of natural language processing biosurveillance methods for identifying influenza from encounter notes. Ann Intern Med (2012) 1.89
Left atrial volume predicts the risk of atrial fibrillation after cardiac surgery: a prospective study. J Am Coll Cardiol (2006) 1.88
Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol (2012) 1.87
Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood (2009) 1.86
Severe pulmonary hypertension in patients with severe aortic valve stenosis: clinical profile and prognostic implications. J Am Coll Cardiol (2002) 1.85
Usefulness of left atrial volume in predicting first congestive heart failure in patients > or = 65 years of age with well-preserved left ventricular systolic function. Am J Cardiol (2005) 1.84
Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides. Nat Med (2002) 1.80
Podocyturia predates proteinuria and clinical features of preeclampsia: longitudinal prospective study. Hypertension (2013) 1.76
Urinary podocyte excretion as a marker for preeclampsia. Am J Obstet Gynecol (2007) 1.75
Smooth muscle cells in human coronary atherosclerosis can originate from cells administered at marrow transplantation. Proc Natl Acad Sci U S A (2003) 1.70
A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. Clin J Am Soc Nephrol (2010) 1.70
Recent trends in the prevalence of coronary disease: a population-based autopsy study of nonnatural deaths. Arch Intern Med (2008) 1.69
Associations of microalbuminuria with brain atrophy and white matter hyperintensities in hypertensive sibships. J Neurol Sci (2008) 1.69
Plasma brain natriuretic peptide to detect preclinical ventricular systolic or diastolic dysfunction: a community-based study. Circulation (2004) 1.67
Genomic association analysis suggests chromosome 12 locus influencing antihypertensive response to thiazide diuretic. Hypertension (2008) 1.66
Estimating the glomerular filtration rate from serum creatinine is better than from cystatin C for evaluating risk factors associated with chronic kidney disease. Kidney Int (2013) 1.66
Left atrial volume in the prediction of first ischemic stroke in an elderly cohort without atrial fibrillation. Mayo Clin Proc (2004) 1.65
Effects of adjustment for referral bias on the sensitivity and specificity of single photon emission computed tomography for the diagnosis of coronary artery disease. Am J Med (2002) 1.65
Normalization and standardization of electronic health records for high-throughput phenotyping: the SHARPn consortium. J Am Med Inform Assoc (2013) 1.64
Viruses as anticancer drugs. Trends Pharmacol Sci (2007) 1.63
Use of log-skew-normal distribution in analysis of continuous data with a discrete component at zero. Stat Med (2008) 1.60
Impaired natriuretic and renal endocrine response to acute volume expansion in pre-clinical systolic and diastolic dysfunction. J Am Coll Cardiol (2011) 1.59
G protein receptor kinase 4 polymorphisms: β-blocker pharmacogenetics and treatment-related outcomes in hypertension. Hypertension (2012) 1.59
A systematic review of population-based studies of infective endocarditis. Chest (2007) 1.59
Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res (2002) 1.57
Genetic control of the alternative pathway of complement in humans and age-related macular degeneration. Hum Mol Genet (2010) 1.57
Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney. Nephrol Dial Transplant (2009) 1.56
Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways. Expert Opin Biol Ther (2009) 1.54
Liver-targeted and peripheral blood alterations of regulatory T cells in primary biliary cirrhosis. Hepatology (2006) 1.53
Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. Mayo Clin Proc (2011) 1.53
Hypertension susceptibility loci and blood pressure response to antihypertensives: results from the pharmacogenomic evaluation of antihypertensive responses study. Circ Cardiovasc Genet (2012) 1.52
Usefulness of immunosuppression for giant cell myocarditis. Am J Cardiol (2008) 1.52
Relation of arterial stiffness to left ventricular diastolic function and cardiovascular risk prediction in patients > or =65 years of age. Am J Cardiol (2006) 1.51
Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation. Nephrol Dial Transplant (2011) 1.51
The changing distribution of arm circumferences in NHANES III and NHANES 2000 and its impact on the utility of the 'standard adult' blood pressure cuff. Blood Press Monit (2003) 1.50
The use of a tropism-modified measles virus in folate receptor-targeted virotherapy of ovarian cancer. Clin Cancer Res (2006) 1.50
Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model. J Natl Cancer Inst (2006) 1.49
Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model. Clin Cancer Res (2009) 1.48